Self-Assessment Modules (SAMs) – 52 CME Credits Available

1. SAM17: Evaluating the Impact of Community-Based Treatment Options for Methamphetamine Use: Findings from the Methamphetamine Treatment Evaluation Study (MATES Trial)
2. SAM19: Concurrent Naltrexone and Prolonged Exposure Therapy for Patients with Comorbid Alcohol Dependence and PTSD
3. SAM20: Extreme Binge Drinking Among 12th-Grade Students in the United States
4. SAM22: Dispelling the Myth of “Smart Drugs”: Cannabis and Alcohol Use Problems Predict Nonmedical Use of Prescription Stimulants for Studying
5. SAM23: Immediate Antecedents of Marijuana Use: An Analysis from Ecological Momentary Assessment
6. SAM24: The Use and Perception of Electronic Cigarettes and Snus Among the U.S. Population
7. SAM25: Effectiveness of Screening and Brief Alcohol Intervention In Primary Care (SIPS Trial)
8. SAM26: Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): A Multisite Trial in the NIDA Clinical Trials Network
10. SAM28: Cannabis Use Is Quantitatively Associated with Nucleus Accumbens and Amygdala Abnormalities in Young Adult Recreational Users
11. SAM29: Association between Stillbirth and Illicit Drug Use and Smoking During Pregnancy
12. SAM30: Graphic Warning Labels in Cigarette Advertisements: Recall and Viewing Patterns
13. SAM31: Varenicline Tartrate for Alcohol Dependence: A Double-Blind, Placebo-Controlled Trial Assessing Efficacy
14. SAM32: Promethazine Misuse Among Methadone Maintenance Patients and Community-Based Injection Drug Users
15. SAM45: Prednisolone or Pentoxifylline for Alcoholic Hepatitis
16. SAM46: Effect of Anxiolytic and Hypnotic Drug Prescriptions on Mortality Hazards: Retrospective Cohort Study
17. SAM47: Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment
18. SAM48: A Prospective Study of Marijuana Use Change and Cessation Among Adolescents
19. SAM49: Methadone and Buprenorphine for Opioid Dependence During Pregnancy: A Retrospective Cohort Study
20. SAM50: Vaccine for Cocaine Dependence: A Randomized Double-Blind Placebo-Controlled Efficacy Trial
21. SAM51: Emergency Department-initiated Buprenorphine/Naloxone Treatment for Opioid Dependence: A Randomized Controlled Trial
22. SAM52: Increasing Incidence of the Neonatal Abstinence Syndrome in U.S. Neonatal ICUs
23. SAM53: Association of Electronic Cigarette Use with Initiation of Combustible Tobacco Product Smoking in Early Adolescence
24. SAM54: Young Adult Sequelae of Adolescent Cannabis Use: An Integrative Analysis
25. SAM57: Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial
26. SAM58: Methadone Continuation versus Forced Withdrawal on Incarceration in a Combined US Prison and Jail: A Randomized, Open-Label Trial
27. SAM59: The Impact of Methadone Maintenance Therapy on Hepatitis C Incidence among Illicit Drug Users
28. SAM60: Randomized Trial of Reduced-Nicotine Standards for Cigarettes
29. SAM61: Medication-Assisted Treatment for Opioid Use Disorders in Correctional Settings: An Ethics Review
31. SAM63: Extended-Release Naltrexone Is Used to Prevent Opioid Relapse in Criminal Justice Offenders
32. SAM65: Sexual Dysfunction in Heroin Dependents by Understanding a Comparison between Methadone and Buprenorphine Maintenance Treatment
33. SAM66: Inability to Access Addiction Treatment Predicts Injection Initiation among Street-Involved Youth in a Canadian Setting
34. SAM68: Detoxification from Opiate Drugs During Pregnancy
35. SAM67: Energy Drink Use is Associated with Alcohol and Substance Use in 8th, 10th and 12th Graders
36. SAM69: Long-Term Outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study
37. SAM70: Interactive Text Message Intervention to Reduce Binge Drinking in Young Adults
38. SAM71: Buprenorphine+Naloxone plus Naltrexone for the Treatment of Cocaine Dependence: The Cocaine Use Reduction with Buprenorphine (CURB) Study
39. SAM72: Comparative Effectiveness of Extended-release Naltrexone versus Buprenorphine-naloxone for Opioid Relapse Prevention (X:BOT): a Multicentre, Open-label, Randomised Controlled Trial
40. SAM73: Opioid-prescribing Patterns of Emergency Physicians and Risk of Long-term Use
41. SAM76: Cognitive Performance in a Placebo-controlled Pharmacotherapy Trial for Youth with Marijuana Dependence
42. SAM79: Mortality Risk During and After Opioid Substitution Treatment: Systematic Review and Meta-Analysis of Cohort Studies
43. SAM80: Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome
44. SAM81: A Randomized Controlled Trial of a Citywide Emergency Department Care Coordination Program to Reduce Prescription Opioid Related Emergency Department Visits

No public access to the source article, fee from publisher may apply:

45. SAM55: The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs*
46. SAM56: Validity of Self-Reported Drug Use Information among Pregnant Women*
47. SAM64: Performance of Tobacco, Alcohol, Prescription Medicine, and Other Substances Use (TAPS) Tool for Substance Use Screening in Primary Care Patients*
48. SAM74: Alcohol Consumption during Adolescence is Associated with Reduced Grey Matter Volumes*
49. SAM75: Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014*
50. SAM77: Correlates of Use of Alcohol Mixed with Energy Drinks among Youth across 10 US Metropolitan Areas*
51. SAM78: Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain*
52. SAM82: Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial*

2019 Addiction e-Practice Test (ADePT) – 24 CME Credits

ACAAM Recommended Activities – 83 CME Credits Available

Best Clinician Resources for Identifying and Responding to Substance Use Among Adolescents and Young Adults – 1 CME

AMSAMs Bundle – 82 CME credits available
This is a compilation of all SAMs including the 52 above. You can only get CME credit once per individual SAM activity.

1. SAM01: Trazodone for Sleep Disturbance During Methadone Maintenance
2. SAM02: Prevalence of Alcohol Use Disorders Before and After Bariatric Surgery
3. SAM03: Persistent Cannabis Users Show Neuropsychological Decline from Childhood to Midlife
4. SAM05: Moderate Alcohol Consumption During Adult Life, Drinking Patterns, And Breast Cancer Risk
5. SAM06: Reduced fMRI Activity Predicts Relapse in Patients Recovering from Stimulant Dependence
6. SAM07: Opiate Substitution Treatment and HIV Transmission in People Who Inject Drugs
7. SAM08: Association Between Opioid Prescribing Patterns And Opioid Overdose-Related Deaths
8. SAM09: Opioids Overdose Education and Nasal Naloxone Distribution (OEND)
9. SAM11: Behavioral Counseling After Screening for Alcohol Misuse in Primary Care
10. SAM12: Brief Screening for Adolescent Nonmedical Users of Prescription Opioids
11. SAM13: Early Start: A Cost–Beneficial Perinatal Substance Abuse Program
12. SAM14: High-Dose Baclofen: A Retrospective Study Among High-Risk Drinkers
13. SAM15: Use of N-Acetylcysteine in Cannabis-Dependent Adolescents
14. SAM16: Effectiveness of Early Interventions for Substance Using Adolescents
15. SAM17: Evaluating the Impact of Community-Based Treatment Options for Methamphetamine Use: Findings from the Methamphetamine Treatment Evaluation Study (MATES Trial)
16. SAM18: Chronic Care Management of Dependence (The AHEAD Trial)
17. SAM19: Concurrent Naltrexone and Prolonged Exposure Therapy for Patients with Comorbid Alcohol Dependence and PTSD
18. SAM20: Extreme Binge Drinking Among 12th-Grade Students in the United States
19. SAM21: Neonatal Abstinence Syndrome, Single-Nucleotide Polymorphisms and Hospital Length of Stay
20. SAM22: Dispelling the Myth of “Smart Drugs”: Cannabis and Alcohol Use Problems Predict Nonmedical Use of Prescription Stimulants for Studying
21. SAM23: Immediate Antecedents of Marijuana Use: An Analysis from Ecological Momentary Assessment
22. SAM24: The Use and Perception of Electronic Cigarettes and Snus Among the U.S. Population
23. SAM25: Effectiveness of Screening and Brief Alcohol Intervention In Primary Care (SIPS Trial)
24. SAM26: Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): A Multisite Trial in the NIDA Clinical Trials Network
25. SAM27: The 10-Year Course of Alcoholics Anonymous Participation and Long-Term Outcomes: A Follow-Up Study of Outpatient Subjects in Project MATCH
26. SAM29: Association between Stillbirth and Illicit Drug Use and Smoking During Pregnancy
27. SAM30: Graphic Warning Labels in Cigarette Advertisements: Recall and Viewing Patterns
28. SAM31: Varenicline Tartrate for Alcohol Dependence: A Double-Blind, Placebo-Controlled Trial Assessing Efficacy
29. SAM32: Promethazine Misuse Among Methadone Maintenance Patients and Community-Based Injection Drug Users
30. SAM34: Brief Intervention for Problem Drug Use in Safety-Net Primary Care Settings: A Randomized Clinical Trial
31. SAM35: Screening and Brief Intervention for Drug Use in Primary Care (The ASPIRE Trial)
32. SAM36: Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial
33. SAM37: Psychedelics and Mental Health: a Population Study
34. SAM38: An Electronic Screen for Triaging Adolescent Substance Use by Risk Levels
35. SAM39: Maintenance Treatment with Varenicline for Smoking Cessation in Patients with Schizophrenia and Bipolar Disorder: a Randomized Clinical Trial
36. SAM40: A Smartphone Application to Support Recovery from Alcoholism: a Randomized Clinical Trial
37. SAM43: Elements That Define Recovery: The Experiential Perspective
38. SAM45: Prednisolone or Pentoxifylline for Alcoholic Hepatitis
39. SAM46: Effect of Anxiolytic and Hypnotic Drug Prescriptions on Mortality Hazards: Retrospective Cohort Study
40. SAM47: Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment
41. SAM48: A Prospective Study of Marijuana Use Change and Cessation Among Adolescents
42. SAM49: Methadone and Buprenorphine for Opioid Dependence During Pregnancy: A Retrospective Cohort Study
43. SAM50: Vaccine for Cocaine Dependence: A Randomized Double-Blind Placebo-Controlled Efficacy Trial
44. SAM51: Emergency Department-initiated Buprenorphine/Naloxone Treatment for Opioid Dependence: A Randomized Controlled Trial
45. SAM52: Increasing Incidence of the Neonatal Abstinence Syndrome in U.S. Neonatal ICUs
46. SAM53: Association of Electronic Cigarette Use with Initiation of Combustible Tobacco Product Smoking in Early Adolescence
47. SAM54: Young Adult Sequelae of Adolescent Cannabis Use: An Integrative Analysis
48. SAM54: Young Adult Sequelae of Adolescent Cannabis Use: An Integrative Analysis
49. SAM57: Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial
50. SAM58: Methadone Continuation versus Forced Withdrawal on Incarceration in a Combined US Prison and Jail: A Randomized, Open-Label Trial
51. SAM59: The Impact of Methadone Maintenance Therapy on Hepatitis C Incidence among Illicit Drug Users
52. SAM60: Randomized Trial of Reduced-Nicotine Standards for Cigarettes
53. SAM61: Medication-Assisted Treatment for Opioid Use Disorders in Correctional Settings: An Ethics Review
54. SAM62: Trends in Concomitant Prescribing of Opioids and Benzodiazepines, 2002-2014
55. SAM63: Extended-Release Naltrexone Is Used to Prevent Opioid Relapse in Criminal Justice Offenders
56. SAM65: Sexual Dysfunction in Heroin Dependents by Understanding a Comparison between Methadone and Buprenorphine Maintenance Treatment
57. SAM66: Inability to Access Addiction Treatment Predicts Injection Initiation among Street-Involved Youth in a Canadian Setting
58. SAM68: Detoxification from Opiate Drugs During Pregnancy
59. SAM67: Energy Drink Use is Associated with Alcohol and Substance Use in 8th, 10th and 12th Graders
60. SAM69: Long-Term Outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study
61. SAM70: Interactive Text Message Intervention to Reduce Binge Drinking in Young Adults
62. SAM71: Buprenorphine+Naloxone plus Naltrexone for the Treatment of Cocaine Dependence: The Cocaine Use Reduction with Buprenorphine (CURB) Study
63. SAM72: Comparative Effectiveness of Extended-release Naltrexone versus Buprenorphine-naloxone for Opioid Relapse Prevention (X:BOT): a Multicentre, Open-label, Randomised Controlled Trial
64. SAM73: Opioid-prescribing Patterns of Emergency Physicians and Risk of Long-term Use
65. SAM76: Cognitive Performance in a Placebo-controlled Pharmacotherapy Trial for Youth with Marijuana Dependence
66. SAM79: Mortality Risk During and After Opioid Substitution Treatment: Systematic Review and Meta-Analysis of Cohort Studies
67. SAM80: Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome
68. SAM81: A Randomized Controlled Trial of a Citywide Emergency Department Care Coordination Program to Reduce Prescription Opioid Related Emergency Department Visits

No public access to the source article, fee from publisher may apply:

69. SAM04: Implementing Rapid HIV Testing With or Without Risk-Reduction Counseling in Drug Treatment Centers*
70. SAM10: Remission From Substance Dependence: Those Who Do and Do Not Seek Help*
71. SAM33: Examining the Specification Validity of the HEDIS Quality Measures for Substance Use Disorders*
72. SAM40: Use of the Nicotine Metabolite Ratio as a Genetically Informed Biomarker of Response to Nicotine Patch or Varenicline for Smoking Cessation: a Randomized, Double-Blind Placebo-Controlled Trial*
73. SAM41: Buprenorphine Treatment for Hospitalized, Opioid-dependent Patients: a Randomized Clinical Trial*
74. SAM43: Changes in Daily Substance Use Among People Experiencing Homelessness and Mental Illness: 24-Month Outcomes Following Randomization to Housing First or Usual Care*
75. SAM55: The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs*
76. SAM56: Validity of Self-Reported Drug Use Information among Pregnant Women*
77. SAM64: Performance of Tobacco, Alcohol, Prescription Medicine, and Other Substances Use (TAPS) Tool for Substance Use Screening in Primary Care Patients*
78. SAM74: Alcohol Consumption during Adolescence is Associated with Reduced Grey Matter Volumes*
79. SAM75: Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014*
80. SAM77: Correlates of Use of Alcohol Mixed with Energy Drinks among Youth across 10 US Metropolitan Areas*
81. SAM78: Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain*
82. SAM82: Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial*

Other Recommended Addiction Medicine Activities – Up to 300 CME Credits Available. 

New activities added periodically.

1. Patient Safety: Principles and Practices (1.5 CME)
2. SafetyQuest: Level One – QI Basics (2 CME)
3. SafetyQuest: Level Two – Moving Beyond QI Basics (2 CME)
4. SafetyQuest: Level Three – Implementing QI Basics (2 CME)
5. SafetyQuest: Level Four – Mastering QI (2 CME)
6. Understanding Addiction (8 CME)
7. Current Best Practices for the Identification and Management of Opioid Use Disorder (8 CME)
8. Fundamentals About the Nature of Addiction for Practitioners Seeking to Learn More About Opioid Use Disorder (8 CME)
9. Prescription Drug Misuse and Addiction: Compassionate Care for a Complex Problem (2 CME)
10. 8 Hour Online MAT Waiver Training (Up to 8 CME)
11. Smokers with Serious Mental Illness: Current Smoking Rates and Treatments (1.25 CME)
12. Psychiatry Synergies: Fall 2018 (.50 CME)
13. Slips and Slip Ups: Managing Buprenorphine in Patients with Co-Occurring Pain and Addiction (1 CME)
14. Opioid Therapy for Pain: An Evidence Review (1 CME)
15. Understanding and Assessing Opioid Use Disorder in Patients with Chronic Pain (1 CME)
16. Opioid Risk Assessment, Mitigation, and Management (1 CME)
17. Opioids for Pain Treatment in Persons with Opioid Use Disorder (1 CME)
18. Opioid Pharmacology and Dosing Management (1 CME)
19. Keys to Communication Success in Opioid Management (1 CME)
20. Managing Pain in the Patient with Opioid Use Disorder: Inpatient Management (1 CME)
21. Pain Management & Opioids (Up to 10 CME)
22. Pain Medicine Management: The Treatment of Opioid Dependence (1 CME)
23. Pain and Addiction: A Clinical Path To Mindfulness (1 CME)
24. The Carlat Addiction Treatment Report May 2017 Issue: Recovery (1 CME)
25. Potential Impairment in the Healthcare Professional and the Physicians Health Program (1.5 CME)
26. Chronic Pain and the Opioid Crisis (1 CME)
27. Adolescent Substance Use and Rx Drug Misuse (1 CME)
29. Identification, Counseling, and Treatment of OUD (8 CME)
30. Collaborative Care Approaches for Mgmt. of OUD (8 CME)

The following are annual live conferences which are available for a fee from the educational providers that have been recommended by The Addiction Medicine Foundation’s Lifelong Learning and Self-Assessment Committee:

1. LIVE - 2018 Addiction Medicine Conference (19.75 CME)
2. LIVE - Addiction Medicine Best Practices of Today & Tomorrow: A Case-based Approach to the Treatment of Addiction (13.5 CME)
3. LIVE - Comprehensive Review of Pain Medicine (5 CME)
4. LIVE - Addiction Medicine for All Providers: Pearls for Practice in a Time for Advocacy (13.75 CME)
5. LIVE - MASAM Pearls in the Addictions: “Priorities in a Time of Crisis and Opportunity” (13.75 CME)
7. LIVE - 2019 Addiction Medicine Conference (19 CME)
8. LIVE - 11th Annual Mississippi Addiction Conference “Addiction Across the Spectrum” (17.75 CME)
10. LIVE – NYSAM’s 15th Annual “Intersection of Science, Treatment, and Policy” Conference (14.75 CME)
11. LIVE - Substance Use Disorders: A Comprehensive Review and Update 2019 (15 CME)
12. LIVE - The State of the Art in Addiction Medicine Conference 2018 (26 CME)
13. LIVE - CSAM 2019 Addiction Medicine Review Course and Board Exam Track (28.75 CME)